Thelansis’s “Chronic Obstructive Pulmonary Disease (COPD) Market Access and Reimbursement Insights Report – 2026″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.
Chronic Obstructive Pulmonary Disease (COPD) is a significant global contributor to chronic illness and premature death. As the third leading cause of death worldwide, its prevalence and fatality rates are projected to rise in the coming decades. The disease is characterized by chronic inflammation that causes structural alterations and constriction in the smaller air passages. This inflammatory process also drives lung tissue damage, resulting in the detachment of alveoli from smaller airways and a decrease in lung elasticity, which ultimately reduces the airways’ ability to remain open during exhalation. To assess the extent of airflow restriction, spirometry serves as the most accessible and dependable measure of lung function, with diagnosis confirmed by a post-bronchodilator FEV1/FVC ratio of less than 0.70. The clinical impact of COPD on an individual is determined not only by the degree of airflow limitation but also by the severity of associated symptoms and the frequency of exacerbations. Because an imperfect correlation exists between the degree of airflow limitation and patient symptoms, modern staging acts as a practical framework that combines spirometric grading with symptom burden and exacerbation risk to guide the initial management plan.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.
*Survey and interview discussion guide are customized based on client requirements
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Chronic Obstructive Pulmonary Disease (COPD) – Market Access and Reimbursement Insights Report – 2026 report
Our team will get in touch with you shortly about the Chronic Obstructive Pulmonary Disease (COPD) – Market Access and Reimbursement Insights Report – 2026 report.